About Ajax Therapeutics
Ajax Therapeutics is a company based in Cambridge (United States) founded in 2019 by Olli Silvennoinen was acquired by Lilly in April 2026. It operates as a HealthTech. Ajax Therapeutics has raised $135 million across 2 funding rounds from investors including Lilly, Schrödinger and Memorial Sloan - Kettering Cancer Center. Ajax Therapeutics offers products and services including AJ1-11095 and AJ1-10502. Ajax Therapeutics operates in a competitive market with competitors including Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others.
- Headquarter Cambridge, United States
- Founders Olli Silvennoinen
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ajax Therapeutics
Ajax Therapeutics offers a comprehensive portfolio of products and services, including AJ1-11095 and AJ1-10502. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
A first-in-class Type II JAK2 inhibitor developed.
A next-generation Type II JAK2 inhibitor researched.
Funding Insights of Ajax Therapeutics
Ajax Therapeutics has successfully raised a total of $135M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $95 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series C — $95.0M
-
First Round
First Round
(01 Jun 2021)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2024 | Amount | Series C - Ajax Therapeutics | Valuation | Goldman Sachs Asset Management | |
| Jun, 2021 | Amount | Series B - Ajax Therapeutics | Valuation | EcoR1 |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ajax Therapeutics
Ajax Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Schrödinger and Memorial Sloan - Kettering Cancer Center. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity firm
|
Founded Year | Domain | Location | |
|
Biotech startups are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Investment in biotechnology companies is facilitated by this firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ajax Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ajax Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ajax Therapeutics Comparisons
Competitors of Ajax Therapeutics
Ajax Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adicet Bio, ImmunoACT, Orca Bio, Ossium Health and Nordic Nanovector, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Immune cell therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cell therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| domain | founded_year | HQ Location |
Ossium Health is focused on bioengineering for improved health.
|
|
| domain | founded_year | HQ Location |
Antibody radionuclide conjugates are developed for haematological cancers.
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for hematopoietic stem cell transplants are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ajax Therapeutics
Frequently Asked Questions about Ajax Therapeutics
When was Ajax Therapeutics founded?
Ajax Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is Ajax Therapeutics located?
Ajax Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Ajax Therapeutics a funded company?
Ajax Therapeutics is a funded company, having raised a total of $135M across 2 funding rounds to date. The company's 1st funding round was a Series B of $40M, raised on Jun 01, 2021.
What does Ajax Therapeutics do?
Ajax Therapeutics is engaged in the development of targeted therapies for hematologic cancers, specifically myeloproliferative neoplasms (MPNs) such as myelofibrosis. Advanced computational chemistry and structural biology are utilized throughout the drug discovery process. A new generation of Type II JAK2 inhibitors is being developed to address unmet medical needs by improving therapeutic efficacy and reducing disease persistence. The company operates in the biotechnology sector, partnering with industry leaders like Schrödinger, Inc. to optimize drug-like properties of small molecules. Solutions are aimed at overcoming limitations of existing Type I JAK2 inhibitors through greater precision and selectivity.
Who are the top competitors of Ajax Therapeutics?
Ajax Therapeutics's top competitors include Orca Bio, Ossium Health and Adicet Bio.
What products or services does Ajax Therapeutics offer?
Ajax Therapeutics offers AJ1-11095 and AJ1-10502.
Who are Ajax Therapeutics's investors?
Ajax Therapeutics has 10 investors. Key investors include Lilly, Schrödinger, Memorial Sloan - Kettering Cancer Center, RA Capital, and Goldman Sachs Asset Management.